ArticlePloS one2015
Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.Molecular imaging and biology · 2020Pooled it
- Multimodal analysis of whole slide images in colorectal cancer.NPJ digital medicine · 2025Article
- PET/CT in assessment of colorectal liver metastases: a comprehensive review with emphasis onClinical & experimental metastasis · 2023Review
- Role of advanced imaging techniques in the evaluation of oncological therapies in patients with colorectal liver metastases.World journal of gastroenterology · 2023Review
- The Value ofDiagnostics (Basel, Switzerland) · 2022Review
- Imaging evaluation of the liver in oncology patients: A comparison of techniques.World journal of hepatology · 2021Review
- A decade of multi-modality PET and MR imaging in abdominal oncology.The British journal of radiology · 2021Review
- Article
- Geometrical Comparison and Quantitative Evaluation ofFrontiers in oncology · 2021Article
- Evaluation ofFrontiers in oncology · 2021Article
- Colorectal cancer: Parametric evaluation of morphological, functional and molecular tomographic imaging.World journal of gastroenterology · 2019Review
- Multiparametric MR for non-invasive evaluation of tumour tissue histological characteristics after radionuclide therapy.NMR in biomedicine · 2019Article
- Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response toTranslational oncology · 2018Article
- Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.Journal of cancer research and clinical oncology · 2017Article
- Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy.European radiology · 2017Article
- Advanced imaging of colorectal cancer: From anatomy to molecular imaging.Insights into imaging · 2016Review
- Article
- Functional MR Imaging Techniques in Oncology in the Era of Personalized Medicine.Magnetic resonance imaging clinics of North America · 2016Review
- Multiparametric MR Imaging in Abdominal Malignancies.Magnetic resonance imaging clinics of North America · 2016Review
- The value of intravoxel incoherent motion model-based diffusion-weighted imaging for outcome prediction in resin-based radioembolization of breast cancer liver metastases.OncoTargets and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimAim of this study was to investigate the potential of 18F-FDG PET, diffusion weighted imaging (DWI) and susceptibility-weighted (T2*) MRI to predict response to systemic treatment in patients with colorectal liver metastases. The predictive values of pretreatment measurements and of early changes one week after start of therapy, were evaluated.
methodsImaging was performed prior to and one week after start of first line chemotherapy in 39 patients with colorectal liver metastases. 18F-FDG PET scans were performed on a PET/CT scanner and DWI and T2* were performed on a 1.5T MR scanner. The maximum standardized uptake values (SUV), total lesion glycolysis (TLG), apparent diffusion coefficient (ADC) and T2* value were assessed in the same lesions. Up to 5 liver metastases per patient were analyzed. Outcome measures were progression free survival (PFS), overall survival (OS) and size response.
resultsPretreatment, high SUVmax, high TLG, low ADC and high T2* were associated with a shorter OS. Low pretreatment ADC value was associated with shorter PFS. After 1 week a significant drop in SUVmax and rise in ADC were observed. The drop in SUV was correlated with the rise in ADC (r=-0.58, p=0.002). Neither change in ADC nor in SUV was predictive of PFS or OS. T2* did not significantly change after start of treatment.
conclusionPretreatment SUVmax, TLG, ADC, and T2* values in colorectal liver metastases are predictive of patient outcome. Despite sensitivity of DWI and 18F-FDG PET for early treatment effects, change in these parameters was not predictive of long term outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.